Tags

Type your tag names separated by a space and hit enter

Desloratadine in combination with montelukast suppresses the dermographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: a randomized, double-blind, placebo-controlled study.
Br J Dermatol. 2006 Dec; 155(6):1279-82.BJ

Abstract

BACKGROUND

Delayed pressure urticaria (DPU) comes under the heading of physical urticaria. Characteristically itchy, tender or painful weals occur at sites of local pressure including the waistband, soles of the feet and palms of the hands. Lesion onset is typically 3-12 h after the application of pressure, and lesions may persist for more than 24 h. The treatment of DPU is often unsatisfactory.

OBJECTIVES

To determine the efficacy of desloratadine and montelukast in the treatment of DPU.

METHODS

The study was conducted in 36 subjects affected by DPU. A challenge test with a dermographometer was administered to confirm the diagnosis. After diagnosis, patients were randomized to receive the following treatment once daily for 2 weeks: (i) oral desloratadine 5 mg plus oral placebo; (ii) oral desloratadine 5 mg plus montelukast 10 mg; and (iii) oral placebo alone.

RESULTS

At rechallenge, patients from the treatment groups (desloratadine plus montelukast group and desloratadine alone group) demonstrated a significant reduction in mean diameter of papules after 70 s of pressure compared with the placebo group (P < 0.05). Moreover, patients treated with desloratadine plus montelukast showed a significant reduction in mean diameter of papules at 70 s of pressure compared with those treated with desloratadine alone (P < 0.05). In addition, the combination was effective in improving clinical parameters (erythema, oedema and pruritus, and number of separate urticarial episodes).

CONCLUSIONS

This study has demonstrated that both desloratadine alone and desloratadine plus montelukast administered once daily yield improvements with respect to the baseline assessment, regarding the suppression of the dermographometer challenge test papule and clinical improvement of urticaria. However, the combination of desloratadine and montelukast was shown to be more efficacious and may therefore be proposed in patients with DPU, in order to avoid corticosteroid therapy.

Authors+Show Affiliations

Department of Medical Clinic, Immunology and Infectious Diseases, Division of Allergy and Clinical Immunology, University of Bari Medical School, Bari, Italy. e.nettis@allergy.uniba.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

17107402

Citation

Nettis, E, et al. "Desloratadine in Combination With Montelukast Suppresses the Dermographometer Challenge Test Papule, and Is Effective in the Treatment of Delayed Pressure Urticaria: a Randomized, Double-blind, Placebo-controlled Study." The British Journal of Dermatology, vol. 155, no. 6, 2006, pp. 1279-82.
Nettis E, Colanardi MC, Soccio AL, et al. Desloratadine in combination with montelukast suppresses the dermographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2006;155(6):1279-82.
Nettis, E., Colanardi, M. C., Soccio, A. L., Ferrannini, A., & Vacca, A. (2006). Desloratadine in combination with montelukast suppresses the dermographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: a randomized, double-blind, placebo-controlled study. The British Journal of Dermatology, 155(6), 1279-82.
Nettis E, et al. Desloratadine in Combination With Montelukast Suppresses the Dermographometer Challenge Test Papule, and Is Effective in the Treatment of Delayed Pressure Urticaria: a Randomized, Double-blind, Placebo-controlled Study. Br J Dermatol. 2006;155(6):1279-82. PubMed PMID: 17107402.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Desloratadine in combination with montelukast suppresses the dermographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: a randomized, double-blind, placebo-controlled study. AU - Nettis,E, AU - Colanardi,M C, AU - Soccio,A L, AU - Ferrannini,A, AU - Vacca,A, PY - 2006/11/17/pubmed PY - 2007/5/9/medline PY - 2006/11/17/entrez SP - 1279 EP - 82 JF - The British journal of dermatology JO - Br J Dermatol VL - 155 IS - 6 N2 - BACKGROUND: Delayed pressure urticaria (DPU) comes under the heading of physical urticaria. Characteristically itchy, tender or painful weals occur at sites of local pressure including the waistband, soles of the feet and palms of the hands. Lesion onset is typically 3-12 h after the application of pressure, and lesions may persist for more than 24 h. The treatment of DPU is often unsatisfactory. OBJECTIVES: To determine the efficacy of desloratadine and montelukast in the treatment of DPU. METHODS: The study was conducted in 36 subjects affected by DPU. A challenge test with a dermographometer was administered to confirm the diagnosis. After diagnosis, patients were randomized to receive the following treatment once daily for 2 weeks: (i) oral desloratadine 5 mg plus oral placebo; (ii) oral desloratadine 5 mg plus montelukast 10 mg; and (iii) oral placebo alone. RESULTS: At rechallenge, patients from the treatment groups (desloratadine plus montelukast group and desloratadine alone group) demonstrated a significant reduction in mean diameter of papules after 70 s of pressure compared with the placebo group (P < 0.05). Moreover, patients treated with desloratadine plus montelukast showed a significant reduction in mean diameter of papules at 70 s of pressure compared with those treated with desloratadine alone (P < 0.05). In addition, the combination was effective in improving clinical parameters (erythema, oedema and pruritus, and number of separate urticarial episodes). CONCLUSIONS: This study has demonstrated that both desloratadine alone and desloratadine plus montelukast administered once daily yield improvements with respect to the baseline assessment, regarding the suppression of the dermographometer challenge test papule and clinical improvement of urticaria. However, the combination of desloratadine and montelukast was shown to be more efficacious and may therefore be proposed in patients with DPU, in order to avoid corticosteroid therapy. SN - 0007-0963 UR - https://www.unboundmedicine.com/medline/citation/17107402/Desloratadine_in_combination_with_montelukast_suppresses_the_dermographometer_challenge_test_papule_and_is_effective_in_the_treatment_of_delayed_pressure_urticaria:_a_randomized_double_blind_placebo_controlled_study_ L2 - https://doi.org/10.1111/j.1365-2133.2006.07533.x DB - PRIME DP - Unbound Medicine ER -